Lumito

6,65 SEK

-7,38 %

Mindre end 1K følgere

LUMITO

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

-7,38 %

-21,76 %

-5,00 %

-70,44 %

-92,11 %

-93,74 %

-98,03 %

-99,41 %

-97,27 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Markedsværdi

22,88 mio. SEK

Aktieomsætning

50,32 t SEK

Omsætning

100 t

EBIT %

-38.300 %

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning t

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

20.2

2026

Årsrapport '25

7.5

2026

Generalforsamling '26

7.5

2026

Delårsrapport Q1'26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelsefor 6 timer siden

Lumito AB publishes year-end report 2025

Selskabsmeddelelse18.2.2026, 08.20

Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging

Selskabsmeddelelse17.2.2026, 14.00

Invitation to webinar in connection with Lumito AB’s year-end report for 2025

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse3.2.2026, 08.40

Lumito initiates pilot project with leading professor in urological cancer research at Lund University

Selskabsmeddelelse30.1.2026, 14.45

Lumito announces timetable for reverse share split and recalculated terms for outstanding warrants of series TO7

Selskabsmeddelelse29.1.2026, 08.15

Lumito receives patent approval in India

Selskabsmeddelelse28.1.2026, 07.30

Two Swedish research customers place orders for Lumito’s SCIZYS Erbium Kit

Selskabsmeddelelse23.1.2026, 13.50

Lumito’s technology presented at The Pathological Society of Great Britain & Ireland Winter Meeting 2026

Selskabsmeddelelse20.1.2026, 15.30

Changes to the Nomination Committee ahead of Lumito’s Annual General Meeting 2026

Selskabsmeddelelse13.1.2026, 08.30

Analyst Group initiates coverage of Lumito

Selskabsmeddelelse12.1.2026, 08.15

Lumito receives order from Swedish research unit

Selskabsmeddelelse8.1.2026, 12.00

Lumito publishes investor letter – 2025 in review and the road ahead

Selskabsmeddelelse19.12.2025, 14.00

The Board of Directors of Lumito proposes a reversed share split

Selskabsmeddelelse18.12.2025, 11.15

Lumito’s technology enables quantification of low abundant cells

Selskabsmeddelelse12.12.2025, 08.00

Lumito strengthens its international presence and participates in Digital Pathology & AI Congress Europe

Selskabsmeddelelse11.12.2025, 09.30

Lumito renews its quality certification, ISO 13485:2016

Selskabsmeddelelse5.12.2025, 13.15

Nomination Committee for Lumito appointed ahead of the 2026 Annual General Meeting

Selskabsmeddelelse2.12.2025, 07.30

Lumito Appoints Chief Business Officer to accelerate commercial growth

Selskabsmeddelelse27.11.2025, 07.30

Lumito AB publishes interim report for the third quarter of 2025

Selskabsmeddelelse25.11.2025, 09.00

Invitation to webinar in connection with Lumito AB’s Q3 2025 Interim Report

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.